SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
CVTX - CV Therapeutics, Inc.
An SI Board Since January 1999
Posts SubjectMarks Bans
411 31 0
Emcee:  Todd N. Weisrock Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
61I see no news. Still going down.scaram(o)uche-11/22/2002
60Tecadenoson Converts PSVT Patients to Normal Heart Rhythm in Phase III TEMPEST Sscaram(o)uche-11/20/2002
59CVT-3146 Increases Coronary Blood Flow Velocity in Phase II Study Tuesday Novembscaram(o)uche-11/19/2002
58CV Therapeutics Announces Four Abstracts to Be Presented at the American Heart Amopgcw-11/14/2002
57Thanks for the clarification on psvt. I could have made that clearer. Unfortunmopgcw-11/12/2002
56Thanks very much! Just a note..... PSVT is not a subset for the trial, but a scaram(o)uche-11/12/2002
55Thanks. I am very curious to read (one day) what is included in NDA. They have Miljenko Zuanic-11/12/2002
54SG conference summary: + Wed P2 data release for 3146, and early p3 next year. mopgcw-11/12/2002
53Yes. <<This Phase III, multi-center, randomized, double-blind, placebo-coMiljenko Zuanic-10/24/2002
52"Results of this trial appears short. No p value and indication for dose remopgcw-10/23/2002
51Results of this trial appears short. No p value and indication for dose responseMiljenko Zuanic-10/22/2002
50Tell me why not to buy this stock here? CV Therapeutics Updates Progress with Tmopgcw-10/22/2002
49CV Therapeutics Reports Third Quarter Financial Results Thursday October 17, 4:mopgcw-10/17/2002
48Cardiovascular Drug Discovery&Development Summit to Feature Next Generation mopgcw-10/15/2002
47First Albany Securities conference call replay at 1-888-203-1112. Passcode 7681mopgcw-9/5/2002
46BusinessWeek Online Picking Stocks for a Market Rebound Tuesday August 27, 9:4mopgcw-8/28/2002
45Circ Res 2002 Aug 23;91(4):278-80 Short-term treatment with ranolazine improvescaram(o)uche-8/28/2002
44Shares off the shelf, Acqua Wellington, $12.5M at $22.28/share. (eom)scaram(o)uche-8/9/2002
43>> DTI recently announced an agreement with Fujisawa Healthcare, Inc. to dscaram(o)uche-7/12/2002
42background, not the study described in the PR...... Curr Opin Cardiol 2002 Jan;scaram(o)uche-7/12/2002
41an old release that was never posted to the thread??...... Friday May 10, 7:00 scaram(o)uche-7/12/2002
40CV Therapeutics Prices $131 Million Public Equity Offering -Dec 4, 2001 07:dalroi-12/4/2001
39Market goes wild on this news. Jason <i> ANAHEIM, Calif., Nov 14 (Reutetnsaf-11/14/2001
38>>PALO ALTO, Calif., Aug 8, 2001 /PRNewswire via COMTEX/ -- CV Therapeutictuck-8/8/2001
37As for side effects, I see that: >>Side effects more common during ranolakeokalani'nui-3/23/2001
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News